Assessment of efficacy, safety, and tolerability of aprepitant in adult patients with chemotherapy-induced vomiting

e20729 Background: Approximately 70 to 80% of all cancer patients receiving chemotherapy experience emesis and 10 to 44% experience anticipatory emesis. Aprepitanta neurokinin1 (NK 1) receptor an...